Pomegranate and breast cancer: Possible mechanisms of prevention

Nutrition Reviews

Volumn 68, Issue 2, 2010, Pages 122-128

  Sturgeon, Susan R ^a,b   Ronnenberg, Alayne G ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b Division of Biostatistics and Epidemiology   (United States)

Author keywords

Breast cancer; Ellagitannins; Estrogen; Pomegranate juice

Indexed keywords

17ALPHA ESTRADIOL; ANTHOCYANIN; AROMATASE; COUMESTROL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ELLAGIC ACID; ELLAGITANNIN; ESTRADIOL; ESTRONE; FLAVONOID; KAEMPFEROL; LUTEOLIN; NARINGENIN; PHYTOESTROGEN; POLYPHENOL; PROSTAGLANDIN E2; QUERCETIN; SEX HORMONE; TESTOSTERONE 17BETA DEHYDROGENASE; VEGETABLE OIL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; HYDROXYSTEROID DEHYDROGENASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER RISK; DIETARY INTAKE; ENZYME INHIBITION; ESTROGEN ACTIVITY; ESTROGEN SYNTHESIS; FRUIT HUSK; HORMONE BLOOD LEVEL; HUMAN; NONHUMAN; PERICARP; PLANT SEED; POMEGRANATE JUICE; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; BEVERAGE; BLOOD; BREAST TUMOR; CHEMISTRY; ENZYMOLOGY; FEMALE; METABOLISM; POMEGRANATE;

LYTHRACEAE;

17-HYDROXYSTEROID DEHYDROGENASES; BEVERAGES; BREAST NEOPLASMS; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; PROGESTINS; PUNICACEAE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 77950347612     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2009.00268.x     Document Type: Review

References (53)

1. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society, Inc.; 2008.
2. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: Prospective studies. Adv Exp Med Biol. 2008;630:148-165.
3. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 2008;98:9-14.
4. Syed DN, Afaq F, Mukhtar H. Pomegranate derived products for cancer chemoprevention. Semin Cancer Biol. 2007;17: 377-385.
5. Syed DN, Suh Y, Afaq F, Mukhtar H. Dietary agents for chemoprevention of prostate cancer. Cancer Lett. 2008;265:167-176.
6. Seeram NP, Schulman R, Heber D. Pomegranates. Ancient Roots to Modern Medicine. Boca Raton, FL: Taylor & Francis Group; 2006.
7. Lansky EP, Newman RA. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol. 2007;109:177-206.
8. Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): A review. Altern Med Rev. 2008;13:128-144.
9. Longtin R. The pomegranate: Nature's power fruit? J Natl Cancer Inst. 2003;95:346-348.
10. Lempert P. Facts, Figures and Future. 2005; Available at: Http://www.factsfiguresfuture.com/archive/june-2005. Accessed 21 December 2009.
11. Agricultural Marketing Resource Center. Pomegranates Profile. 2009; Available at: Http://www.agmrc.org/commodities-products/fruits/pomegranates.cfm. Accessed 21 December 2009.
12. Mori-Okamoto J, Otawara-Hamamoto Y, Yamato H, Yoshimura H. Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. J Ethnopharmacol. 2004;92:93-101.
13. Patton D. Health Benefits Drive Pomegranate Juice Sales in UK. 2009; Available at: Http://www.nutraingredientsusa. com/Publications/Food-Beverage- Nutrition/ Nutraingredients.com/Consumer-Trends/Health-benefitsdrive- pomegranate-juice-sales-in-UK. Accessed 20 March 2009.
14. van Elswijk DA, Schobel UP, Lansky EP, Irth H, van der Greef J. Rapid dereplication of estrogenic compounds in pomegranate (Punica granatum) using on-line biochemical detection coupled to mass spectrometry. Phytochemistry. 2004;65: 233-241.
15. Artik N. Determination of phenolic compounds in pomegranate juice by using HPLC. Fruit Processing. 1998;8:492-499.
16. Noda Y, Kaneyuki T, Mori A, Packer L. Antioxidant activities of pomegranate fruit extract and its anthocyanidins: Delphinidin, cyanidin, and pelargonidin. J Agric Food Chem. 2002;50: 166-171.
17. Hernandez F, Melgarejo P, Tomas-Barberan FA, Artes F. Evolution of juice anthocyanins during ripening of new selected pomegranate (Punica granatum) clones. Eur Food Res Technol. 1999;210:39-42.
18. Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem. 2000;48:4581-4589.
19. Satomi H, Umemura K, Ueno A, Hatano T, Okuda T, Noro T. Carbonic anhydrase inhibitors from the pericarps of Punica granatum L. Biol Pharm Bull. 1993;16:787-790.
20. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr. 2006;136:2481-2485.
21. Seeram NP, Aviram M, Zhang Y, et al. Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the united states. J Agric Food Chem. 2008;56: 1415-1422.
22. Larrosa M, Gonzalez-Sarrias A, Garcia-Conesa MT, Tomas-Barberan FA, Espin JC. Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. J Agric Food Chem. 2006;54:1611-1620.
23. Seeram NP, Zhang Y, McKeever R, et al. Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food. 2008; 11:390-394.
24. Schubert SY, Lansky EP, Neeman I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J Ethnopharmacol. 1999;66:11-17.
25. Moneam NM, el Sharaky AS, Badreldin MM. Oestrogen content of pomegranate seeds. J Chromatogr. 1988;438:438-442.
26. Speroff L, Glass RJ, Kass NG. Clinical Gynecologic Endocrinology and Infertility. Baltimore, MD: Lippincott Williams & Wilkins; 1999.
27. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev. 1993;15:48-65.
28. Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: A quantitative review. Cancer Causes Control. 1997;8:922-928.
29. KimND, Mehta R, YuW, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat. 2002;71:203-217.
30. Wang C, Makela T, Hase T, Adlercreutz H, Kurzer MS. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol. 1994;50:205-212.
31. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol. 2004;31(2 Suppl):22-29.
32. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep. 2000;7:1377-1381.
33. Trimboli AJ,Waite BM, Atsumi G, et al. Influence of coenzyme A-independent transacylase and cyclooxygenase inhibitors on the proliferation of breast cancer cells. Cancer Res. 1999;59:6171-6177.
34. DuBois RN. Aspirin and breast cancer prevention: The estrogen connection. JAMA. 2004;291:2488-2489.
35. Moysich KB, Beehler GP, Zirpoli G, Choi JY, Baker JA. Use of common medications and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:1564-1595.
36. Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM. Bioavailable constituents/metabolites of pomegranate (Punica granatum L) preferentially inhibit COX2 activity ex vivo and IL-1beta-induced PGE2 production in human chondrocytes in vitro. J Inflamm (Lond). 2008;5:9.
37. Mehta R, Lansky EP. Breast cancer chemopreventive properties of pomegranate (Punica granatum) fruit extracts in a mouse mammary organ culture. Eur J Cancer Prev. 2004;13: 345-348.
38. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71:1397-1421.
39. Garbacki N, Angenot L, Bassleer C, Damas J, Tits M. Effects of prodelphinidins isolated from Ribes nigrum on chondrocyte metabolism and COX activity. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:434-441.
40. Kurzer MS. Hormonal effects of soy isoflavones: studies in premenopausal and postmenopausal women. J Nutr. 2000; 130(Suppl):S660-S661.
41. Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab. 1999;84:4017-4024.
42. Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 1996;5: 785-794.
43. Cutler GJ, Nettleton JA, Ross JA, et al. Dietary flavonoid intake and risk of cancer in postmenopausal women: The Iowa Women's Health Study. Int J Cancer. 2008;123:664-671.
44. Bosetti C, Spertini L, Parpinel M, et al. Flavonoids and breast cancer risk in Italy. Cancer Epidemiol Biomarkers Prev. 2005;14:805-808.
45. Peterson J, Lagiou P, Samoli E, et al. Flavonoid intake and breast cancer risk: A case-control study in Greece. Br J Cancer. 2003;89:1255-1259.
46. Fink BN, Steck SE, Wolff MS, et al. Dietary flavonoid intake and breast cancer survival among women on Long Island. Cancer Epidemiol Biomarkers Prev. 2007;16:2285-2292.
47. Sharaf A, Nigm SA. The oestrogenic activity of pomegranate seed oil. J Endocrinol. 1964;29:91-92.
48. Dean PDG, Exley D, Goodwin TW. Steroid oestrogens in plants: Re-estimation of oestrone in pomegranate seeds. Phytochemistry. 1971;10:2215.
49. Heftmann E, Ko S, Bennet RD. Identification of estrone in pomegranate seeds. Phytochemistry. 1966;5:1337.
50. Choi DW, Kim JY, Choi SH, et al. Identification of steroid hormones in pomegranate (Punica granatum) using HPLC and GC-mass spectrometry. Food Chem. 2005;96:562.
51. Papoutsi Z, Kassi E, Tsiapara A, Fokialakis N, Chrousos GP, Moutsatsou P. Evaluation of estrogenic/antiestrogenic activity of ellagic acid via the estrogen receptor subtypes ERalpha and ERbeta. J Agric Food Chem. 2005;53:7715-7720.
52. Aiyer HS, Srinivasan C, Gupta RC. Dietary berries and ellagic acid diminish estrogen-mediated mammary tumorigenesis in ACI rats. Nutr Cancer. 2008;60:227-234.
53. Key TJ, Allen NE. Hormones and breast cancer. IARC Sci Publ. 2002;156:273